Allogene Therapeutics Files 8-K for Ethics Code, Exhibits
Ticker: ALLO · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
Related Tickers: ALLO
TL;DR
ALLO filed an 8-K for ethics code updates and financial exhibits. Standard procedure.
AI Summary
Allogene Therapeutics, Inc. filed an 8-K on October 7, 2024, reporting an amendment to its Code of Ethics and the filing of financial statements and exhibits. The earliest event reported was on October 3, 2024. The company is located at 210 East Grand Avenue, South San Francisco, CA 94080.
Why It Matters
This filing indicates routine corporate governance updates and the submission of necessary financial documentation to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing pertains to routine corporate governance and financial reporting, not a material event impacting the company's operations or financial health.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- October 3, 2024 (date) — Earliest event reported
- October 7, 2024 (date) — Date of report
- 210 East Grand Avenue, South San Francisco, CA 94080 (location) — Principal executive offices
FAQ
What specific items are being amended or waived in the Code of Ethics?
The filing states "Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics" as an item information, but does not detail the specific amendments or waivers within the provided text.
What financial statements and exhibits are being filed?
The filing lists "Financial Statements and Exhibits" as an item information, but the specific contents of these documents are not detailed in the provided text.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is October 3, 2024.
What is the principal executive office address for Allogene Therapeutics, Inc.?
The principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080.
What is the SEC file number for Allogene Therapeutics, Inc.?
The SEC file number for Allogene Therapeutics, Inc. is 001-38693.
Filing Stats: 764 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-10-07 16:28:00
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value per share ALLO The Nasdaq Sto
Filing Documents
- allo-20241003.htm (8-K) — 27KB
- allo-20241003x8kex141.htm (EX-14.1) — 98KB
- 0001737287-24-000062.txt ( ) — 271KB
- allo-20241003.xsd (EX-101.SCH) — 2KB
- allo-20241003_lab.xml (EX-101.LAB) — 21KB
- allo-20241003_pre.xml (EX-101.PRE) — 12KB
- allo-20241003_htm.xml (XML) — 3KB
05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics. On October 3, 2024, the Audit Committee of the Board of Directors of Allogene Therapeutics, Inc. (the "Company") adopted and approved certain amendments to the Company's Code of Business Conduct and Ethics (the "Code") that applies to all directors, officers, employees and certain consultants and contractors of the Company ("Covered Persons"). The existing Code was refreshed and updated by further enhancing and clarifying the Code's standards requiring compliance with applicable governmental laws, rules, and regulations as well as Company policies and procedures. The amendments include, among other changes: (i) changes to reflect a concurrent amendment to the Company's insider trading policy, (ii) additional expressly stated categories of information that may not be shared with competitors pursuant to antitrust laws, (iii) an additional expressly stated category of direct or indirect financial benefit that a Covered Person must consider in connection with potential conflicts of interest, (iv) changes to the procedures that must be followed prior to any Covered Person investing or participating in an outside business opportunity that is directly related to the Company's line of business, (v) expanded restrictions designed to maintain the integrity of the Company's records and public disclosures, (vi) expanded obligations related to fair dealing, (vii) expanded restrictions against giving or receiving certain gifts and entertainment, (viii) expanded requirements related to the protection and use of Company assets, (ix) an update to the scope of the Company's official spokespersons' authority with respect to media and public disclosures, (x) express requirements to comply with data privacy and cybersecurity matters, and (xi) an express requirement that Covered Persons comply with all other Company policies that are developed to support and reinforce the principles
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 14.1 Allogene Therapeutics, Inc. Code of Business Conduct and Ethics 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALLOGENE THERAPEUTICS, INC. By: /s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer Dated: October 7, 2024